ArcDia, a manufacturer of multianalyte point-of-care diagnostic system for respiratory tract infections, has raised EUR2.7m to expand its mariPOC diagnostics system.

Lifeline Ventures along with the existing investors Biothom, Veraventure and private investors have led the funding round.

mariPOC, in a swab test at point-of-care, is capable to diagnose nine common viruses and bacteria that are clinically important in respiratory tract infections – such as influenza A/B, RS-virus and parainfluenza 1/2/3 viruses, while enabling targeted treatment decisions.

ArcDia CEO Aleksi Soini said simply, instead of performing multiple tests that take time to administer and diagnose, and may be difficult to read, mariPOC provides automated analysis for nine pathogens in one sample in 20 minutes – and with a clear, readable answer.

"No other diagnostics test platform has been able to provide this functionality and cost-effectiveness to enable respiratory tract infections testing at point-of-care," Soini said.

Lifeline Ventures founding partner Timo Ahopelto said before mariPOC, point-of-care multianalyte diagnostic platforms have been too complicated, expensive, difficult-to-use and inaccurate for respiratory tract infections.

"mariPOC is taking into account clinical, economic and scientific mattersto enable multianalyte diagnostics for this world’s most prevalent disease cluster," Ahopelto said.